Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse.

Leukemia - 1 Sept 2021

Al Hinai Adil S A, Grob Tim, Rijken Melissa, Kavelaars François G, Zeilemaker Annelieke, Erpelinck-Verschueren Claudia A J, Sanders Mathijs A, Löwenberg Bob, Jongen-Lavrencic Mojca, Valk Peter J M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Follow-Up Studies
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Protein Phosphatase 2C

Share to Remission Induction

Source

Identifiers

PMID: 33589749
DOI: 10.1038/s41375-021-01155-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse.PMID 33589749Read ↗

NPM1 gene mutations can be confidently identified in blood DNA months before de novo AML onset.Semantic proximity Read ↗

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration.Semantic proximity Read ↗

MRD in AML: time for redefinition of CR?Semantic proximity Read ↗

The Landscape of KMT2A‐PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical OutcomeSemantic proximity Read ↗

NPM1-mutated AML: how many diseases?Semantic proximity Read ↗

First new drug approval for AML in 15 years.Semantic proximity Read ↗

Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation.Semantic proximity Read ↗

Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.Semantic proximity Read ↗

Overlapping features of therapy-related and de novo NPM1-mutated AML.Semantic proximity Read ↗

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.Semantic proximity Read ↗

NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation.Semantic proximity Read ↗

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.